Profound Medical Corp. PROF
Medical/Dental Instruments · data as of November 13, 2026
Profound Medical Corp. (PROF) is a healthcare company listed in the US with a market value of about $272M. In the twelve months to September 30, 2026 it had revenue of $24M and net income of -$32M, a net margin of -137.5%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 17% a year, a 5-year average ROIC of -48%.
About Profound Medical
Profound Medical is listed in the US and classified in medical/dental instruments. Revenue went from $4M in 2019 to $16M in 2025, growth of about 25.2% a year. It was profitable in 0 of the last 7 years in our data. It spends 128% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $24M | $16M | $11M | $7M | $7M | $7M | $7M | $4M |
| Net income | -$32M | -$43M | -$28M | -$28M | -$29M | -$31M | -$22M | -$15M |
| Free cash flow | -$32M | -$38M | — | — | — | -$22M | — | — |
| EPS (diluted) | $-0.94 | $-1.16 | $-0.76 | $-0.77 | $-0.78 | $-0.84 | $-0.59 | $-0.42 |
| Net margin | -137.5% | -264.4% | -260.4% | -393.4% | -429.1% | -446.7% | -296.0% | -364.7% |
| ROIC | — | -45.8% | -50.4% | -73.0% | -42.5% | -29.7% | -15.3% | -50.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $11.14, 50% above the current price; targets range from $10.00 to $12.00; the consensus rating is “Strong buy”; expected EPS is $-0.93 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Profound Medical pay a dividend?
Not currently.
Is Profound Medical a good stock to buy?
We do not give buy or sell advice. Profound Medical scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.